The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models Martina JabloñskiMaría Sol RodríguezIsabel Alicia Lüthy Original Article 19 September 2023 Pages: 485 - 499
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment Mototsugu OyaShuichi KanekoYutaka Okayama Retraction Note Open access 16 September 2023 Pages: 523 - 523
Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective Mohamed Ben-EltrikiGehana ShankarSubrata Deb Review Article 15 September 2023 Pages: 419 - 437
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients Alireza AbbaspourMehdi DehghaniOmidreza Firuzi Original Article 05 September 2023 Pages: 475 - 483
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer Yukitaka ShibataNatsumi MatsumotoKen-ichi Fujita Original Article 31 August 2023 Pages: 465 - 474
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation Shiyu HeQianhang ShaoQian Jiang Original Article 25 August 2023 Pages: 399 - 410
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection Cléa TardyAlicja PuszkielAudrey Thomas Schoemann Short Communication 24 August 2023 Pages: 169 - 175
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy Junichi NakagawaTakenori TakahataTakenori Niioka Original Article 23 August 2023 Pages: 391 - 398
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure Hirotaka ImamakiMitsuaki OuraYoshinao Ozaki Short Communication Open access 22 August 2023 Pages: 161 - 167
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer Kenji NakahamaMotohiro IzumiTomoya Kawaguchi Original Article 22 August 2023 Pages: 381 - 390
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype John F. MarcellettiBranimir I. Sikic Original Article 21 August 2023 Pages: 369 - 380
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations Chukwunonso K. Nwabufo Review Article 18 August 2023 Pages: 89 - 105
Chemotherapy periodization to maximize resistance training adaptations in oncology Jonathan H. C. NunesPaola S. CellaRafael Deminice Original Article 15 August 2023 Pages: 357 - 367
Mechanism of cisplatin resistance in gastric cancer and associated microRNAs Changqing LiuShan LiYunlian Tang Review Article 03 August 2023 Pages: 329 - 340
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study Yuxiang MaQun ChenHongyun Zhao Clinical Trial Report 31 July 2023 Pages: 411 - 418
An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose Bart A. JessenPaul CornwellTimothy Hart Original Article Open access 28 July 2023 Pages: 455 - 464
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma Chun-Ting HuShao-Jun PeiGuo-Hui Fu Original Article 28 July 2023 Pages: 341 - 355
Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic–pharmacokinetic and exposure–response analysis Hayato YokotaKazuhiro SatoMasatomo Miura Original Article 27 July 2023 Pages: 315 - 324
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma Hidemi NishiKunihito GotohHidetoshi Eguchi Original Article Open access 26 July 2023 Pages: 303 - 314
Azithromycin inhibits glioblastoma angiogenesis in mice via inducing mitochondrial dysfunction and oxidative stress Xiulan ZhangHaibo Xu Original Article 24 July 2023 Pages: 291 - 302
Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer Jin Ho BaekByung Woog KangJong Gwang Kim Original Article 22 July 2023 Pages: 279 - 290
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs Xiaowen WangFang ChenBing Han Review Article 19 July 2023 Pages: 253 - 270
Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis Takuya KanekoKosuke DokiMasato Homma Original Article 17 July 2023 Pages: 271 - 278
Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report Shelby BarnettAye Chan NyeinGareth J. Veal Short Communication Open access 15 July 2023 Pages: 325 - 328
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities Sean G. Rudd Review Article Open access 15 July 2023 Pages: 241 - 251
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab Emmanuelle JacquetFiona PhamNicolas Albin Original Article 13 July 2023 Pages: 223 - 228
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo Dongbo WangHuina WuJing Nie Original Article 11 July 2023 Pages: 211 - 221
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data Nastya KassirPhyllis ChanRené Bruno Original Article Open access 06 July 2023 Pages: 205 - 210
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers Dongxue LiuLinlin HuHua Shao Review Article 06 July 2023 Pages: 165 - 179
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors Mats NågårdMei-Lin Ah-SeeGanesh M. Mugundu Original Article Open access 02 July 2023 Pages: 193 - 203
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series Taro YamanakaKohji TakemuraYuji Miura Short Communication 28 June 2023 Pages: 235 - 240
Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer Gaoqi XuDihong YangLuo Fang Original Article 28 June 2023 Pages: 181 - 192
A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer Charles A. KunosRichard PiekarzTimothy J. Kinsella Clinical Trial Report Open access 27 June 2023 Pages: 151 - 155
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study Mats NågårdMei-Lin Ah-SeeGanesh M. Mugundu Original Article Open access 27 June 2023 Pages: 141 - 150
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients M. ValeryK. SalehC. Castilla-Llorente Short Communication 24 June 2023 Pages: 229 - 233
Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study Mohsen ShafieiPeter GalettisPrunella Blinman Original Article 23 June 2023 Pages: 135 - 139
The role of alternative splicing in lung cancer Xuelian NingZitong FuShuoshuo Wang Review Article 19 June 2023 Pages: 83 - 95
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling Xinghua ZhouJian KangYue Cheng Original Article 15 June 2023 Pages: 119 - 134
Pharmacology and pharmacokinetics of elacestrant Jan H. BeumerJulia Foldi Short Communication 14 June 2023 Pages: 157 - 163
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation Sarina A. Piha-PaulChieh TsengFunda Meric-Bernstam Original Article Open access 14 June 2023 Pages: 107 - 118
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis Lan HongXiuzhen WangGenhai Zhu Original Article Open access 05 June 2023 Pages: 71 - 81
A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis Philipp KönigRoman ZhulenkoGerd Bendas Original Article Open access 05 June 2023 Pages: 57 - 69
Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia Minu SinghDivya BhaskarAmita Trehan Original Article 31 May 2023 Pages: 51 - 56
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative Amanda B. KaganBlake S. MosesCurt I. Civin Original Article 30 May 2023 Pages: 39 - 50
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02) Tsukasa HasegawaRyo AriyasuMakoto Nishino Original Article 27 May 2023 Pages: 29 - 37
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma Drew W. RascoTheresa MedinaAnthony J. Olszanski Original Article Open access 23 May 2023 Pages: 15 - 28
Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database Mitsuaki OuraFumiya OguroYoshitaka Nishikawa Original Article 19 May 2023 Pages: 7 - 14
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies Alexis C. BoulterBarry J. MaurerDavid E. Gerber Original Article 18 May 2023 Pages: 97 - 105
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma Katelyn N. PurvisHope D. SwansonJamie E. Flerlage Original Article 18 May 2023 Pages: 1 - 6
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers Chaoying HuYanping ZhangLan Zhang Clinical Trial Report 11 May 2023 Pages: 523 - 529
